Search | Clinical Trials Finder

Conditions: Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions: Solriamfetol Oral Tablet [Sunosi], Placebo; Drug
Lead sponsor: Rochester Center for Behavioral Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester Hills, Michigan

Conditions: Bipolar Disorder
Interventions: AZD4451, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: MPOX
Interventions: Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 44
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more

Conditions: Atopic Asthma
Interventions: Oral Silymarin, Oral Silymarin, maintenance dose, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Depression
Interventions: EVT 101, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Oceanside, California • San Diego, California • Tampa, Florida + 11 more

Conditions: Schizophrenia
Interventions: Ziprasidone, Olanzapine, Placebo Comparator; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Other Acute Postoperative Pain
Interventions: Diclofenac Test (lower dose), Diclofenac Test (upper dose), Celecoxib, Placebo; Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 1 more

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 76
States / cities: Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more

Conditions: Bipolar Disorder, Depression
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 42
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more

Conditions: Atrial Fibrillation
Interventions: dapagliflozin, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Portland, Maine • Detroit, Michigan • Rochester, New York

Conditions: Cognitive Impairment Associated With Schizophrenia
Interventions: MEM 3454, Placebo for MEM 3454; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 44
States / cities: Lemon Grove, California • Newport Beach, California • Oceanside, California + 29 more

Conditions: Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Interventions: Tart Cherry, Omega 3 FA (Fish Oil); Drug
Lead sponsor: Philip Chang; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Torrance, California

Conditions: Insomnia
Interventions: Placebo ethanol, Ethanol, Placebo, Gabapentin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Normal Healthy Subjects
Interventions: HT-6184, HT-6184 Placebo; Drug
Lead sponsor: Halia Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Healthy Participants
Interventions: Lu AG06474, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neuroblastoma, Neuroendocrine Tumor
Interventions: Retinoic Acid, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 6 Months to 30 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy Volunteers
Interventions: Rhodiola rosea (low dose), Rhodiola rosea (high dose), Placebo capsules; Dietary Supplement
Lead sponsor: Jacksonville State University; Other
Eligibility: 18 Weeks to 40 Weeks
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Jacksonville, Alabama

Conditions: Schizophrenia
Interventions: ITI-007, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 11
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 8 more

Conditions: Depressive Disorder
Interventions: saredutant (SR48968), placebo, escitalopram; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years to 64 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Morphea, Scleroderma, Localized, Scleroderma
Interventions: FCX-013, veledimex; Genetic · Drug
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: BMS-830216, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Major Depressive Disorder
Interventions: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD, BCI-024 (Buspirone), Matching placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 9
States / cities: Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more

Conditions: Osteoarthritis, Osteoarthritis, Knee, Pain, Arthralgia, Joint Pain
Interventions: Oxycodone CR (standard pain medication), JNJ-42160443, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 36
States / cities: Tucson, Arizona • Carmichael, California • Pismo Beach, California + 33 more

Conditions: Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions: PPD10558, Atorvastatin, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 67
States / cities: Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more

Search by objective public record fields.

A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451

Study of Tecovirimat for Human Mpox Virus

Randomized Controlled Trial of Silymarin in Asthma

Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

Study of Diclofenac Capsules to Treat Pain Following Bunionectomy

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects

Study to Evaluate HT-6184 in Healthy Subjects

A Study Investigating Lu AG06474 in Healthy Young Participants

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults

A Trial to Assess the Antipsychotic Efficacy of ITI-007

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

Safety Study to Evaluate BMS-830216 in Healthy Subjects

Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)